YAP1 and neoplasm: Moreover, one clinical study shows that the combined expression of YAP in tumour cells and non-lymphocytic stromal cells is associated with the reduced efficacy of anthracycline-taxane-based neoadjuvant chemotherapy in TNBC patients in terms of PCR rate [85].